Winette T.A. van der Graaf
威内特·范德格拉夫
MD, PhD
Professor of Medical Oncology; Chair, Sarcoma Group内科肿瘤学教授；肉瘤研究组主席
👥Biography 个人简介
Winette van der Graaf is a leading sarcoma oncologist at the Netherlands Cancer Institute and professor at the Institute of Cancer Research in London, with a distinguished career advancing systemic therapies for soft tissue sarcomas. She was the principal investigator of the PALETTE phase III trial, which established pazopanib as the first anti-angiogenic agent approved for non-adipocytic soft tissue sarcomas. Her translational research focuses on predictive biomarkers of TKI response and novel immunotherapy combinations in sarcoma.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
PALETTE Trial — Pazopanib in Soft Tissue Sarcoma
Led the PALETTE phase III randomized trial demonstrating that pazopanib significantly improved progression-free survival versus placebo in patients with metastatic non-adipocytic soft tissue sarcoma after prior chemotherapy, leading to EMA and FDA approval.
Biomarker Research in Sarcoma TKI Therapy
Conducted comprehensive translational analyses correlating molecular and genomic features with outcomes in sarcoma patients receiving TKI therapy, identifying potential predictive biomarkers to guide patient selection.
European Sarcoma Clinical Trials Network
Served as chair of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), coordinating international randomized clinical trials and establishing European infrastructure for sarcoma drug development.
Representative Works 代表性著作
Pazopanib for Metastatic Soft-Tissue Sarcoma (PALETTE): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial
The Lancet (2012)
PALETTE phase III trial establishing pazopanib as an approved second-line option in non-adipocytic soft tissue sarcoma.
Pembrolizumab in Advanced Soft-Tissue Sarcoma and Bone Sarcoma (SARC028): A Multicentre, Two-Cohort, Single-Arm, Open-Label, Phase 2 Trial
The Lancet Oncology (2017)
Phase 2 study exploring PD-1 blockade activity across sarcoma subtypes, identifying undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma as potentially responsive subtypes.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 威内特·范德格拉夫 的研究动态
Follow Winette T.A. van der Graaf's research updates
留下邮箱，当我们发布与 Winette T.A. van der Graaf（The Netherlands Cancer Institute (NKI-AVL) / The Institute of Cancer Research London）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment